search
Back to results

When to INDuce for OverWeight? (WINDOW) (WINDOW)

Primary Purpose

Pregnancy, Obesity, Parturition

Status
Recruiting
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Elective induction of labor at 39 gestational weeks and 0 to 3 days
Sponsored by
University of Aarhus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pregnancy focused on measuring Induction of labor, Expectant management, Cesarean section

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

• Pregnant women with pre- or early pregnancy BMI ≥ 30 kg/m2

Exclusion Criteria:

  • Legal or ethical considerations: maternal age <18 years, language difficulties requiring an interpreter or translator
  • Multiple pregnancy
  • Previous caesarean section
  • Uncertain gestational age, defined as gestational age determined by other measurements than the Crown-Rump length (CRL) Measurement
  • Planned elective caesarean section at time of randomisation
  • Fetal contraindications to IOL at time of randomisation: e.g. non-cephalic presentation, or other fetal conditions contraindicating vaginal delivery
  • Fetal contraindications to expectant management at time of randomisation
  • Maternal contraindications to IOL at time of randomisation: e.g. placenta previa/accreta, vasa previa
  • Maternal contraindications to expectant management at time of randomisation: e.g. maternal medical conditions, ultrasonically diagnosed oligohydramnios (DVP< 2 cm), signs of labour including pre-labour rupture of membranes (PROM)

Sites / Locations

  • Aarhus University HospitalRecruiting
  • Herlev HospitalRecruiting
  • Gødstrup Regional HospitalRecruiting
  • North Zealand's HospitalRecruiting
  • Hvidovre HospitalRecruiting
  • Kolding HospitalRecruiting
  • Rigshospitalet Juliane Marie CentreRecruiting
  • Nykøbing Falster HospitalRecruiting
  • Odense University HospitalRecruiting
  • Randers Regional HospitalRecruiting
  • Zealand University HospitalRecruiting
  • Viborg HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Elective induction of labour

Expectant management

Arm Description

Elective induction of labour at 39 gestational weeks and 0 to 3 days.

Awaiting spontaneous labor.

Outcomes

Primary Outcome Measures

Caesarean section
number (no.)

Secondary Outcome Measures

Mode of delivery if not by caesarean
Vaginal delivery - no. Vaginal assisted delivery - no.
Mode of delivery
Caesarean section - percent Vaginal delivery - percent Vaginal assisted delivery - percent
Vaginal assisted delivery
Forceps - no. Ventouse - no.
Indication for caesarean section (more than one indication is possible)
Labour dystocia - no. Fetal distress - no. Maternal request - no. Suspected macrosomia - no. Non-cephalic presentation - no. Extensive vaginal bleeding - no. Suspected uterine rupture - no. Maternal or fetal complication/condition (free text) - no. Other indication for caesarean section (free text) - no.
Indication for vaginal assisted delivery (more than one is possible)
Labour dystocia - no. Fetal distress - no. Maternal request - no. Other indication for assisted vaginal delivery (free text) - no.
Use of epidural
no.
Damage to internal organs (bladder, bowel or ureters)
no.
Uterine scar dehiscense or rupture
no.
Complications
Minor shoulder dystocia defined as the need for McRobert's maneuver - no. Major shoulder dystocia defined as the need for procedures other than McRobert's maneuver - no. Clinical suspicion of abruption of the placenta leading to an intervention in labour - no. Cord prolapse - no. Maternal fever defined as temperature >38,2 / >38,0 degrees celsius with / without epidural - no. Perineal 3rd degree laceration - no. Perineal 4th degree laceration - no. Episiotomy - no.
Postpartum haemorrhage
Blood loss >500ml - no. Blood loss >1000ml - no. Blood transfusion - no. Time Frame [0-2 days postpartum]
Hysterectomy
no.
Postpartum morbidity
Puerperal infection treated in hospital - no. Other severe postpartum conditions treated in hospital (free text) - no.
Maternal admission to Intensive Care Unit
no.
Maternal cardiopulmonary arrest
no.
Maternal death
no.
Primary neonatal composite including any of the following;
Perinatal death (stillbirth and neonatal) The need for respiratory support if admitted to a neonatal department (intubation and mechanical ventilation, oxygen, continuous positive airway pressure (CPAP), or high-flow nasal cannula (HNFC)). Time Frame [within 72 hours after birth] Apgar score < 4 at 5 minutes Hypoxic-ischemic encephalopathy (defined as the need for therapeutic hypothermia) Seizures Infection (defined as antibiotic treatment continuously for 7 days minimum) Meconium aspiration syndrome Birth trauma (bone fracture, Duchenne-Erbs palsy, or retinal hemorrhage) Intracranial or subgaleal hemorrhage Hypotension requiring vasopressor support
Components of the primary neonatal composite will additionally be reported separately
Perinatal death (stillbirth and neonatal) - no. The need for respiratory support if admitted to a neonatal department (intubation and mechanical ventilation, oxygen, continuous positive airway pressure (CPAP), or high-flow nasal cannula (HNFC)). Time Frame [within 72 hours after birth] - no. Apgar score < 4 at 5 minutes - no. Hypoxic-ischemic encephalopathy (defined as the need for therapeutic hypothermia) - no. Seizures - no. Infection (defined as antibiotic treatment continuously for 7 days minimum) - no. Meconium aspiration syndrome - no. Birth trauma (bone fracture, Duchenne-Erbs palsy, or retinal hemorrhage) - no. Intracranial or subgaleal hemorrhage - no. Hypotension requiring vasopressor support - no.
Neonatal trauma composite including any of the following;
Birth trauma (bone fracture, Duchenne-Erbs palsy, or retinal hemorrhage) Intracranial or subgaleal hemorrhage
Neonatal asphyxia composite including any of the following;
Apgar score < 4 at 5 minutes Umbilical cord pH-value < 7.0 (allow missing data) Umbilical cord standard base excess (sBE) < -15.0 mmol/l (allow missing data) Seizures Hypoxic-ischemic encephalopathy (defined as the need for therapeutic hypothermia)
Apgar score at 5 minutes
Apgar score <4 - no. Apgar score of 4-7 - no.
Umbilical cord arterial and venous blood sample (allow missing data)
pH-value < 7.0 - no. sBE < -15.0 mmol/l - no.
Neonatal admission
no.
Respiratory support during neonatal admission
CPAP (y/n) - no. HNFC (y/n) - no. Oxygen supplement treatment (y/n) - no. Ventilator treatment (y/n) - no.
Other treatment during neonatal admission
Therapeutic hypothermia (y/n) - no. Vasopressor support (y/n) - no. Antibiotic treatment continuously for 7 days minimum (y/n) - no.

Full Information

First Posted
October 12, 2020
Last Updated
October 1, 2023
Sponsor
University of Aarhus
Collaborators
Aarhus University Hospital, Randers Regional Hospital, Herning Hospital, Central Jutland Regional Hospital, Nykøbing Falster County Hospital, Odense University Hospital, Rigshospitalet Juliane Marie Centret, Kolding Sygehus, Herlev Hospital, Hvidovre University Hospital, North Zealand's Hospital, Zealand University Hospital - Roskilde
search

1. Study Identification

Unique Protocol Identification Number
NCT04603859
Brief Title
When to INDuce for OverWeight? (WINDOW)
Acronym
WINDOW
Official Title
When to INDuce for OverWeight? - a Randomised Controlled Trial (WINDOW)
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 19, 2020 (Actual)
Primary Completion Date
June 2026 (Anticipated)
Study Completion Date
June 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Aarhus
Collaborators
Aarhus University Hospital, Randers Regional Hospital, Herning Hospital, Central Jutland Regional Hospital, Nykøbing Falster County Hospital, Odense University Hospital, Rigshospitalet Juliane Marie Centret, Kolding Sygehus, Herlev Hospital, Hvidovre University Hospital, North Zealand's Hospital, Zealand University Hospital - Roskilde

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The rate of overweight and obese women becoming pregnant is increasing. Obesity in pregnancy along with delivery by cesarean section in obese women is associated with several complications as compared to normal weight women. The longer the woman is pregnant, the longer she is at risk. In an otherwise low-risk pregnant woman at term, it is an ongoing clinical dilemma, whether the benefits of elective induction of labor and termination of the pregnancy will outweigh the potential harms from concomitant induction and delivery process. The proposed study is a randomized controlled study of elective induction versus expectant management in obese women. The study will be carried out as a national multicenter study with inclusion of 1900 participants from Danish delivery wards. The null hypothesis is that the caesarean section rate is similar with elective induction of labor at 39 weeks of gestation, compared with expectant management among pregnant women with pre- or early pregnancy BMI≥30.
Detailed Description
Background The World Health Organization (WHO) defines overweight as a body mass index (BMI) of ≥25 kg/m2 and obesity as a BMI of ≥30 kg/m2. Overweight and obesity are rising dramatically worldwide. In fertile women, the prevalence of obesity is one third in the United States, 20% in the United Kingdom, and 12-13% in Denmark. The association between obesity in pregnancy and the risk of gestational complications increases with increasing BMI. Among other complications, obesity in pregnancy is associated with increased risk of caesarean delivery. Delivery by caesarean section further adds significant risks of wound infection or other infectious morbidity in obese women as compared to normal weight women. The longer the woman is pregnant, the longer the risk of pregnancy complications remains. In an otherwise low-risk pregnant woman at term, it is an on-going clinical dilemma, whether the benefits of elective induction of labor (eIOL) and termination of the pregnancy will outweigh the potential harms from the concomitant induction and delivery process. Regarding delivery complications, based on data from historical cohorts, eIOL has traditionally been associated with an increased risk of caesarean section and instrumental delivery. Therefore, expectant management has been the preferred clinical option. This interpretation has now been challenged by a randomized trial (ARRIVE) with >6000 low-risk pregnant women where eIOL at 39 weeks of gestation was associated with lower caesarean delivery rates. There are no randomized studies in obese women, but two larger observational studies did find lower odds of caesarean delivery in obese women with eIOL as compared to awaiting labor onset. Hence, a randomized trial that would compare caesarean delivery among obese women whose labor is induced with those expectantly managed is warranted. The proposed study will provide new and important knowledge into the area of induction of labor among overweight and obese women with potential great international impact for the future raising number of pregnant women in this subgroup. With this trial, the investigators aim to compare the risk of caesarean section in obese (BMI ≥ 30 kg/m2), but otherwise low-risk women with eIOL as compared to expectant management. Materials and methods The study is a multicenter randomized controlled trial with an allocation ratio of 1:1 in the two following arms: Intervention arm/elective induction of labor in pregnancy at 39 gestational week and 0 to 3 days: Induction is performed according to local policy for induction of labor. Comparison arm/expectant management: Waiting for spontaneous onset of labor unless a situation develops necessitating either induction of labor or caesarean section. 1900 low-risk pregnant women with a pre- or early pregnancy BMI ≥ 30 carrying a singleton pregnancy will be recruited from the Danish delivery wards. In each trial site, a physician investigator will be responsible for the enrolment, the electronically randomization, and data collection. The primary endpoint is the caesarean section rate. Among others there will be secondary endpoints on instrumental delivery, onset of labor, methods of induction, perinatal and postpartum complications both maternal and neonatal along with data on women's experience on birth measured by a questionnaire survey four to six weeks post-partum. Ethics The study will be conducted in accordance with the ethical principles outlined in the latest version of the 'Declaration of Helsinki' and the 'Guideline for Good Clinical Practice' related to experiments on humans. The Central Denmark Region Committee on Biomedical Research Ethics, and The Danish Health Authorities have approved the study. Perspectives In perspective, more than 39% of the world's population is overweight and 13% are obese by the WHO classification. Pregnant overweight women are at increased risk of pregnancy and delivery complications, and there is a need to improve maternity care for this subgroup of women. The results of this trial have the potential to generate important knowledge for the improvement of delivery in obese women and they will add key information to an on-going discussion of the effects of labor induction before term. Any possible harm or disadvantage to the individual study participant is outweighed by the possible benefit to the increasing number of obese women who will be pregnant in the future.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pregnancy, Obesity, Parturition
Keywords
Induction of labor, Expectant management, Cesarean section

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1900 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Elective induction of labour
Arm Type
Experimental
Arm Description
Elective induction of labour at 39 gestational weeks and 0 to 3 days.
Arm Title
Expectant management
Arm Type
No Intervention
Arm Description
Awaiting spontaneous labor.
Intervention Type
Procedure
Intervention Name(s)
Elective induction of labor at 39 gestational weeks and 0 to 3 days
Other Intervention Name(s)
eIOL
Intervention Description
Elective induction of labor (eIOL) according to local policies
Primary Outcome Measure Information:
Title
Caesarean section
Description
number (no.)
Time Frame
At delivery
Secondary Outcome Measure Information:
Title
Mode of delivery if not by caesarean
Description
Vaginal delivery - no. Vaginal assisted delivery - no.
Time Frame
At delivery
Title
Mode of delivery
Description
Caesarean section - percent Vaginal delivery - percent Vaginal assisted delivery - percent
Time Frame
At delivery
Title
Vaginal assisted delivery
Description
Forceps - no. Ventouse - no.
Time Frame
At delivery
Title
Indication for caesarean section (more than one indication is possible)
Description
Labour dystocia - no. Fetal distress - no. Maternal request - no. Suspected macrosomia - no. Non-cephalic presentation - no. Extensive vaginal bleeding - no. Suspected uterine rupture - no. Maternal or fetal complication/condition (free text) - no. Other indication for caesarean section (free text) - no.
Time Frame
At delivery
Title
Indication for vaginal assisted delivery (more than one is possible)
Description
Labour dystocia - no. Fetal distress - no. Maternal request - no. Other indication for assisted vaginal delivery (free text) - no.
Time Frame
At delivery
Title
Use of epidural
Description
no.
Time Frame
At delivery
Title
Damage to internal organs (bladder, bowel or ureters)
Description
no.
Time Frame
At delivery to 30 days postpartum
Title
Uterine scar dehiscense or rupture
Description
no.
Time Frame
At delivery
Title
Complications
Description
Minor shoulder dystocia defined as the need for McRobert's maneuver - no. Major shoulder dystocia defined as the need for procedures other than McRobert's maneuver - no. Clinical suspicion of abruption of the placenta leading to an intervention in labour - no. Cord prolapse - no. Maternal fever defined as temperature >38,2 / >38,0 degrees celsius with / without epidural - no. Perineal 3rd degree laceration - no. Perineal 4th degree laceration - no. Episiotomy - no.
Time Frame
At delivery
Title
Postpartum haemorrhage
Description
Blood loss >500ml - no. Blood loss >1000ml - no. Blood transfusion - no. Time Frame [0-2 days postpartum]
Time Frame
0-2 hours postpartum
Title
Hysterectomy
Description
no.
Time Frame
At delivery to 30 days postpartum
Title
Postpartum morbidity
Description
Puerperal infection treated in hospital - no. Other severe postpartum conditions treated in hospital (free text) - no.
Time Frame
0-30 days postpartum
Title
Maternal admission to Intensive Care Unit
Description
no.
Time Frame
Enrollment to 30 days postpartum
Title
Maternal cardiopulmonary arrest
Description
no.
Time Frame
Enrollment to 30 days postpartum
Title
Maternal death
Description
no.
Time Frame
Enrollment to 30 days postpartum
Title
Primary neonatal composite including any of the following;
Description
Perinatal death (stillbirth and neonatal) The need for respiratory support if admitted to a neonatal department (intubation and mechanical ventilation, oxygen, continuous positive airway pressure (CPAP), or high-flow nasal cannula (HNFC)). Time Frame [within 72 hours after birth] Apgar score < 4 at 5 minutes Hypoxic-ischemic encephalopathy (defined as the need for therapeutic hypothermia) Seizures Infection (defined as antibiotic treatment continuously for 7 days minimum) Meconium aspiration syndrome Birth trauma (bone fracture, Duchenne-Erbs palsy, or retinal hemorrhage) Intracranial or subgaleal hemorrhage Hypotension requiring vasopressor support
Time Frame
Enrollment to 28 days of life
Title
Components of the primary neonatal composite will additionally be reported separately
Description
Perinatal death (stillbirth and neonatal) - no. The need for respiratory support if admitted to a neonatal department (intubation and mechanical ventilation, oxygen, continuous positive airway pressure (CPAP), or high-flow nasal cannula (HNFC)). Time Frame [within 72 hours after birth] - no. Apgar score < 4 at 5 minutes - no. Hypoxic-ischemic encephalopathy (defined as the need for therapeutic hypothermia) - no. Seizures - no. Infection (defined as antibiotic treatment continuously for 7 days minimum) - no. Meconium aspiration syndrome - no. Birth trauma (bone fracture, Duchenne-Erbs palsy, or retinal hemorrhage) - no. Intracranial or subgaleal hemorrhage - no. Hypotension requiring vasopressor support - no.
Time Frame
Enrollment to 28 days of life
Title
Neonatal trauma composite including any of the following;
Description
Birth trauma (bone fracture, Duchenne-Erbs palsy, or retinal hemorrhage) Intracranial or subgaleal hemorrhage
Time Frame
At delivery to 28 days of life
Title
Neonatal asphyxia composite including any of the following;
Description
Apgar score < 4 at 5 minutes Umbilical cord pH-value < 7.0 (allow missing data) Umbilical cord standard base excess (sBE) < -15.0 mmol/l (allow missing data) Seizures Hypoxic-ischemic encephalopathy (defined as the need for therapeutic hypothermia)
Time Frame
At delivery to 28 days of life
Title
Apgar score at 5 minutes
Description
Apgar score <4 - no. Apgar score of 4-7 - no.
Time Frame
5 minutes of life
Title
Umbilical cord arterial and venous blood sample (allow missing data)
Description
pH-value < 7.0 - no. sBE < -15.0 mmol/l - no.
Time Frame
0-30 minutes of life
Title
Neonatal admission
Description
no.
Time Frame
0-72 hours of life
Title
Respiratory support during neonatal admission
Description
CPAP (y/n) - no. HNFC (y/n) - no. Oxygen supplement treatment (y/n) - no. Ventilator treatment (y/n) - no.
Time Frame
0-28 days of life
Title
Other treatment during neonatal admission
Description
Therapeutic hypothermia (y/n) - no. Vasopressor support (y/n) - no. Antibiotic treatment continuously for 7 days minimum (y/n) - no.
Time Frame
0-28 days of life
Other Pre-specified Outcome Measures:
Title
Neonatal characteristics 1
Description
Female sex - no. Birth weight > 4500 grams (y/n) - no.
Time Frame
At delivery
Title
Neonatal characteristics 2
Description
- Mean birth weight - grams
Time Frame
At delivery
Title
Maternal experience on birth
Description
Childbirth Experience Questionnaire Scoring range is 1 to 4 where higher ratings reflect more positive experiences
Time Frame
4-6 weeks postpartum
Title
Maternal postnatal depression
Description
Major Depression Inventory (MDI) Edinburgh Postnatal Depression Score Scoring range is 1 to 4 where higher ratings reflect more positive experiences
Time Frame
4-6 weeks postpartum

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: • Pregnant women with pre- or early pregnancy BMI ≥ 30 kg/m2 Exclusion Criteria: Legal or ethical considerations: maternal age <18 years, language difficulties requiring an interpreter or translator Multiple pregnancy Previous caesarean section Uncertain gestational age, defined as gestational age determined by other measurements than the Crown-Rump length (CRL) Measurement Planned elective caesarean section at time of randomisation Fetal contraindications to IOL at time of randomisation: e.g. non-cephalic presentation, or other fetal conditions contraindicating vaginal delivery Fetal contraindications to expectant management at time of randomisation Maternal contraindications to IOL at time of randomisation: e.g. placenta previa/accreta, vasa previa Maternal contraindications to expectant management at time of randomisation: e.g. maternal medical conditions, ultrasonically diagnosed oligohydramnios (DVP< 2 cm), signs of labour including pre-labour rupture of membranes (PROM)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lise Q Krogh, MD
Phone
0045 51242102
Email
lise.qvirin.krogh@clin.au.dk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lise Q Krogh, MD
Organizational Affiliation
Aarhus University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Julie Glavind, MD, PhD
Organizational Affiliation
Aarhus University Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Sidsel Boie, MD, PhD
Organizational Affiliation
Randers Regional Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Jens Fuglsang, MD, PhD
Organizational Affiliation
Aarhus University Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Tine B Henriksen, MD, PhD
Organizational Affiliation
Aarhus University Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Jim Thornton, MD, PhD
Organizational Affiliation
Nottingham University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Katja A Taastrøm, Midwife, MSc
Organizational Affiliation
Aarhus University Hospital
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Anne Cathrine M Kjeldsen, Midwife, MSc
Organizational Affiliation
Aarhus University Hospital
Official's Role
Study Chair
Facility Information:
Facility Name
Aarhus University Hospital
City
Aarhus
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lise Q Krogh, MD
Facility Name
Herlev Hospital
City
Herlev
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lene Huusom, MD, PhD
Facility Name
Gødstrup Regional Hospital
City
Herning
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Iben Sundtoft, MD, PhD
Facility Name
North Zealand's Hospital
City
Hillerød
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hanne B Westergaard, MD, PhD
Facility Name
Hvidovre Hospital
City
Hvidovre
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lone Krebs, MD, PhD
Facility Name
Kolding Hospital
City
Kolding
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Anne Cathrine H Munk, MD
Facility Name
Rigshospitalet Juliane Marie Centre
City
København
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Kristina Renault, MD, DMSc
Facility Name
Nykøbing Falster Hospital
City
Nykøbing Falster
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jeannet Lauenborg, MD, PhD
Facility Name
Odense University Hospital
City
Odense
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christina Vinter, MD, PhD
Facility Name
Randers Regional Hospital
City
Randers
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pinar Bor, MD, PhD
Facility Name
Zealand University Hospital
City
Roskilde
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nana Wiberg, MD
Facility Name
Viborg Hospital
City
Viborg
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lise Clausen, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The final dataset will be publicly available in an anonymised form using an open data repository (i.e. CERN) or another equivalent database. All relevant trial-related documents will be shared along with the data.
IPD Sharing Time Frame
Beginning three months and ending three years after the publication of the last trial results.
IPD Sharing Access Criteria
Data will be available for any research purpose to all interested parties who have approval from an independent review committee. Interested parties will be able to request the data by contacting the trial sponsor. Authorship of publications emerging from the shared data will follow standard authorship guidelines and will include authors from the WINDOW study group depending on the nature of their involvement.
Citations:
PubMed Identifier
35470194
Citation
Krogh LQ, Boie S, Henriksen TB, Thornton J, Fuglsang J, Glavind J. Induction of labour at 39 weeks versus expectant management in low-risk obese women: study protocol for a randomised controlled study. BMJ Open. 2022 Apr 25;12(4):e057688. doi: 10.1136/bmjopen-2021-057688.
Results Reference
derived

Learn more about this trial

When to INDuce for OverWeight? (WINDOW)

We'll reach out to this number within 24 hrs